Carcinogenesis Advance Access originally published online on October 20, 2006
Carcinogenesis 2007 28(3):704-712; doi:10.1093/carcin/bgl200
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study
1 Division of Cancer Epidemiology and Genetics, National Cancer Institute Rockville, MD, USA
2 The University of Sydney, Sydney Australia
3 National Centre for HIV Epidemiology and Clinical Research, Sydney Australia
4 St Vincent's Hospital, Sydney Australia
5 Viral Epidemiology Section, AVP SAIC-Frederick, NCI-Frederick, Frederick, MD, USA
6 Core Genotyping Facility, National Cancer Institute Gaithersburg, MD, USA
*To whom correspondence should be addressed at: Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 8121, MSC 7240, Rockville, MD 20892-7240, USA. Tel: +1 301 451 5036; Fax: +1 301 402 1819; Email: purduem{at}mail.nih.gov
Recent findings suggest that genetic polymorphisms in TNF and IL10 are associated with an increased risk of non-Hodgkin lymphoma (NHL), particularly for diffuse large B-cell lymphoma (DLBCL). To further investigate the contribution of common genetic variation in key cytokine and innate immunity genes to the etiology of NHL, we genotyped participants in a case–control study of NHL conducted in Australia (545 cases, 498 controls). We investigated 36 single nucleotide polymorphisms in IL10, TNF and 21 other immune function genes. We observed an elevated risk of DLBCL with the IL10 –3575T>A polymorphism [TA genotype: odds ratio (OR) = 1.32, 95% confidence interval (CI) = 0.86–2.02; AA, OR = 1.84, 95% CI = 1.10–3.08; trend test, P = 0.02]. Our most noteworthy TNF finding was an association between –857C>T and a decreased risk of NHL (CT or TT, OR = 0.59, 95% CI = 0.42–0.84, P = 0.003) and particularly follicular lymphoma (OR = 0.40, 95% CI = 0.23–0.68, P = 0.0009). Additionally, TNF –863C>A was associated with an elevated risk of DLBCL (CA, OR = 1.45, 95% CI = 0.95–2.21; AA, OR = 2.06, 95% CI = 0.88–4.83; trend test, P = 0.02). Our findings offer further evidence that variation in the IL10 and TNF loci influences NHL risk. Additional studies are needed to clarify the genetic and biologic basis for these relationships.
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FDR, false-discovery rate; FPRP, false-positive report probability; HWE, Hardy–Weinberg equilibrium; NHL, non-Hodgkin lymphoma.
Received July 7, 2006;
revised October 11, 2006;
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. F. Skibola, P. M. Bracci, A. Nieters, A. Brooks-Wilson, S. de Sanjose, A. M. Hughes, J. R. Cerhan, D. R. Skibola, M. Purdue, E. Kane, et al. Tumor Necrosis Factor (TNF) and Lymphotoxin-{alpha} (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium Am. J. Epidemiol., February 1, 2010; 171(3): 267 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Morton, M. P. Purdue, T. Zheng, S. S. Wang, B. Armstrong, Y. Zhang, I. Menashe, N. Chatterjee, S. Davis, Q. Lan, et al. Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1259 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Colt, N. Rothman, R. K. Severson, P. Hartge, J. R. Cerhan, N. Chatterjee, W. Cozen, L. M. Morton, A. J. De Roos, S. Davis, et al. Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma Blood, February 26, 2009; 113(9): 1899 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Purdue, Q. Lan, S. S. Wang, A. Kricker, I. Menashe, T.-Z. Zheng, P. Hartge, A. E. Grulich, Y. Zhang, L. M. Morton, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma Carcinogenesis, February 1, 2009; 30(2): 275 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, S. Han, S. Wang, X. Zhou, M. Zhang, J. Dong, X. Shi, N. Qian, X. Wang, Q. Wei, et al. Interactions of IL-12A and IL-12B Polymorphisms on the Risk of Cervical Cancer in Chinese Women Clin. Cancer Res., January 1, 2009; 15(1): 400 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Cerhan, W. Liu-Mares, Z. S. Fredericksen, A. J. Novak, J. M. Cunningham, N. E. Kay, A. Dogan, M. Liebow, A. H. Wang, T. G. Call, et al. Genetic Variation in Tumor Necrosis Factor and the Nuclear Factor-{kappa}B Canonical Pathway and Risk of Non-Hodgkin's Lymphoma Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3161 - 3169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Anderson, R. M. Pfeiffer, J. S. Rapkin, G. Gridley, L. Mellemkjaer, K. Hemminki, M. Bjorkholm, N. E. Caporaso, and O. Landgren Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma J. Clin. Oncol., October 20, 2008; 26(30): 4958 - 4965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Kristinsson, M. Bjorkholm, L. R. Goldin, M. L. McMaster, I. Turesson, and O. Landgren Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden Blood, October 15, 2008; 112(8): 3052 - 3056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era Blood, October 1, 2008; 112(7): 2694 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Cerhan, S. M. Ansell, Z. S. Fredericksen, N. E. Kay, M. Liebow, T. G. Call, A. Dogan, J. M. Cunningham, A. H. Wang, W. Liu-Mares, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma Blood, December 15, 2007; 110(13): 4455 - 4463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.V. Brenner, M.A. Butler, S.S. Wang, A.M. Ruder, N. Rothman, P.A. Schulte, S.J. Chanock, H.A. Fine, M.S. Linet, and P.D. Inskip Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma Carcinogenesis, December 1, 2007; 28(12): 2543 - 2547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Domingo-Domenech, Y. Benavente, E. Gonzalez-Barca, C. Montalban, J. Guma, R. Bosch, S. S. Wang, Q. Lan, D. Whitby, A. Fernandez de Sevilla, et al. Impact of interleukin-10 polymorphisms ( 1082 and 3575) on the survival of patients with lymphoid neoplasms Haematologica, November 1, 2007; 92(11): 1475 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Purdue, Q. Lan, A. Kricker, C. M. Vajdic, N. Rothman, and B. K. Armstrong Vitamin D receptor gene polymorphisms and risk of non-Hodgkin's lymphoma Haematologica, August 1, 2007; 92(8): 1145 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Skibola, J. D. Curry, and A. Nieters Genetic susceptibility to lymphoma Haematologica, July 1, 2007; 92(7): 960 - 969. [Abstract] [Full Text] [PDF]
|
|